Alkem Laboratories Ltd (ALKEM) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+0.92%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 10.4%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 18.9%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹5,257.32

200-Day DMA ● Overlay

₹4,875.96

14-Day RSI ● Overlay

55.2 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹62,625 Cr

Large cap

Stock P/E (TTM) Valuation

27.9x

Price / EPS

Book Value (₹) Assets

₹1,156.0

P/B: 4.5x

ROE (%) Quality

18.9%

Net Profit / Equity

ROCE (%) Efficiency

21.2%

EBIT / Capital

Dividend Yield Yield

1.02%

Face Value: ₹10

Debt / Equity Solvency

0.15x

Manageable

EPS (TTM) Per Share

₹187.08

Trailing 12M

OPM (%) Spread

20.0%

EBITDA Margin

Free Cash Flow Cash

₹1,476 Cr

CFO - Capex

About Alkem Laboratories Ltd

Alkem Laboratories Ltd (ALKEM) is an Indian publicly listed company operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 14.4% × Turnover: 0.85x × Leverage: 1.15x = ROE: 18.9%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.15.
• Delivers solid shareholder returns with an ROE of 18.9%.

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹15,081 Cr

Latest PAT

₹2,204 Cr

EPS (TTM)

₹187.08

OPM %

20.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹3,506 Cr	₹3,657 Cr	₹3,846 Cr	₹3,996 Cr
Operating Profit (EBITDA)	₹680.23 Cr	₹724.11 Cr	₹776.82 Cr	₹823.27 Cr
OPM %	19.4%	19.8%	20.2%	20.6%
Interest Expense	₹54.42 Cr	₹57.93 Cr	₹62.15 Cr	₹65.86 Cr
Depreciation	₹81.63 Cr	₹86.89 Cr	₹93.22 Cr	₹98.79 Cr
Profit before Tax (PBT)	₹544.18 Cr	₹579.29 Cr	₹621.45 Cr	₹658.62 Cr
Net Profit (PAT)	₹408.13 Cr	₹434.47 Cr	₹466.09 Cr	₹493.96 Cr
EPS in ₹	₹45.40	₹47.35	₹49.79	₹51.75

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹5,731 Cr	₹6,485 Cr	₹7,390 Cr	₹8,445 Cr	₹9,652 Cr	₹10,406 Cr	₹11,160 Cr	₹12,970 Cr	₹14,025 Cr	₹14,779 Cr	₹15,081 Cr	₹15,684 Cr
Expenses	₹4,688 Cr	₹5,266 Cr	₹5,971 Cr	₹6,739 Cr	₹7,673 Cr	₹8,387 Cr	₹8,794 Cr	₹10,272 Cr	₹11,276 Cr	₹11,824 Cr	₹12,020 Cr	₹12,469 Cr
Operating Profit	₹1,043 Cr	₹1,219 Cr	₹1,419 Cr	₹1,706 Cr	₹1,979 Cr	₹2,019 Cr	₹2,366 Cr	₹2,698 Cr	₹2,749 Cr	₹2,956 Cr	₹3,061 Cr	₹3,215 Cr
OPM %	18.2%	18.8%	19.2%	20.2%	20.5%	19.4%	21.2%	20.8%	19.6%	20%	20.3%	20.5%
Interest	₹73.01 Cr	₹85.34 Cr	₹99.32 Cr	₹119.42 Cr	₹138.50 Cr	₹141.31 Cr	₹165.61 Cr	₹188.84 Cr	₹192.43 Cr	₹206.91 Cr	₹214.30 Cr	₹225.07 Cr
Depreciation	₹125.16 Cr	₹146.30 Cr	₹170.26 Cr	₹204.72 Cr	₹237.44 Cr	₹242.25 Cr	₹283.91 Cr	₹323.72 Cr	₹329.88 Cr	₹354.71 Cr	₹367.37 Cr	₹385.83 Cr
Profit before Tax	₹938.70 Cr	₹1,097 Cr	₹1,277 Cr	₹1,535 Cr	₹1,781 Cr	₹1,817 Cr	₹2,129 Cr	₹2,428 Cr	₹2,474 Cr	₹2,660 Cr	₹2,755 Cr	₹2,894 Cr
Net Profit	₹704.02 Cr	₹822.92 Cr	₹957.70 Cr	₹1,152 Cr	₹1,336 Cr	₹1,363 Cr	₹1,597 Cr	₹1,821 Cr	₹1,856 Cr	₹1,995 Cr	₹2,066 Cr	₹2,170 Cr
EPS in Rs	74.20	83.97	95.68	109.35	124.97	134.74	144.50	167.93	181.60	191.36	195.27	203.08

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹657.56 Cr	₹751.50 Cr	₹883.01 Cr	₹1,033 Cr	₹1,184 Cr	₹1,315 Cr	₹1,428 Cr	₹1,578 Cr	₹1,710 Cr	₹1,822 Cr	₹1,879 Cr
Reserves & Surplus	₹8,548 Cr	₹9,770 Cr	₹11,479 Cr	₹13,433 Cr	₹15,387 Cr	₹17,097 Cr	₹18,562 Cr	₹20,516 Cr	₹22,226 Cr	₹23,691 Cr	₹24,424 Cr
Borrowings (Debt)	₹1,282 Cr	₹1,465 Cr	₹1,722 Cr	₹2,015 Cr	₹2,308 Cr	₹2,564 Cr	₹2,784 Cr	₹3,077 Cr	₹3,334 Cr	₹3,554 Cr	₹3,664 Cr
Total Liabilities	₹16,439 Cr	₹18,788 Cr	₹22,075 Cr	₹25,833 Cr	₹29,590 Cr	₹32,878 Cr	₹35,696 Cr	₹39,454 Cr	₹42,742 Cr	₹45,560 Cr	₹46,969 Cr
Fixed Assets	₹7,891 Cr	₹9,018 Cr	₹10,596 Cr	₹12,400 Cr	₹14,203 Cr	₹15,782 Cr	₹17,134 Cr	₹18,938 Cr	₹20,516 Cr	₹21,869 Cr	₹22,545 Cr
Total Assets	₹16,439 Cr	₹18,788 Cr	₹22,075 Cr	₹25,833 Cr	₹29,590 Cr	₹32,878 Cr	₹35,696 Cr	₹39,454 Cr	₹42,742 Cr	₹45,560 Cr	₹46,969 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹1,465 Cr	₹1,669 Cr	₹1,954 Cr	₹2,198 Cr	₹2,524 Cr	₹2,768 Cr	₹3,053 Cr	₹3,460 Cr	₹3,745 Cr	₹3,989 Cr	₹4,071 Cr
Cash from Investing (CFI)	-₹908.56 Cr	-₹1,035 Cr	-₹1,211 Cr	-₹1,363 Cr	-₹1,565 Cr	-₹1,716 Cr	-₹1,893 Cr	-₹2,145 Cr	-₹2,322 Cr	-₹2,473 Cr	-₹2,524 Cr
Cash from Financing (CFF)	-₹468.94 Cr	-₹534.07 Cr	-₹625.25 Cr	-₹703.40 Cr	-₹807.61 Cr	-₹885.77 Cr	-₹976.95 Cr	-₹1,107 Cr	-₹1,198 Cr	-₹1,277 Cr	-₹1,303 Cr
Free Cash Flow (FCF)	₹738.57 Cr	₹841.15 Cr	₹984.77 Cr	₹1,108 Cr	₹1,272 Cr	₹1,395 Cr	₹1,539 Cr	₹1,744 Cr	₹1,887 Cr	₹2,011 Cr	₹2,052 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	19.2%	19.6%	20%	20.4%	20.8%	21.2%	21.6%	22%	22.4%	22.8%	23.2%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹2,857.22 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹5,448.00

DCF Fair Value

₹2,857.22

Graham Number

₹2,205.89

Margin of Safety

-52.9%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹2,857.22

Premium / Overvalued (Margin: -52.9%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹2,780	₹2,755	₹2,730	₹2,706
10%	₹2,832	₹2,806	₹2,781	₹2,756
12%	₹2,883	₹2,857	₹2,831	₹2,806
14%	₹2,935	₹2,908	₹2,882	₹2,856

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹2,857	Fairly Valued
Benjamin Graham Number	₹2,206	Market Priced
Historical Sector P/E	₹4,116	Premium
EV / EBITDA Multiplier	₹5,720	In-Line
Free Cash Flow Yield Model	₹5,339	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

5.8 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.15x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 20.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

49.70%

FIIs (Foreign)

10.42%

DIIs (Domestic)

22.64%

Government

0.15%

Public / Retail

17.25%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	50.18%	50.06%	49.94%	49.82%	49.70%	49.58%	49.46%	49.34%
• Promoter & Promoter Group Family Trusts	23.86%	23.86%	23.86%	23.86%	23.86%	23.86%	23.86%	23.86%
• Operating Holding Companies & LLPs	18.89%	18.89%	18.89%	18.89%	18.89%	18.89%	18.89%	18.89%
• Key Executive Promoters (Individual)	6.96%	6.96%	6.96%	6.96%	6.96%	6.96%	6.96%	6.96%
+ FIIs (Foreign Portfolio)	10.13%	10.20%	10.28%	10.35%	10.42%	10.49%	10.56%	10.64%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	22.45%	22.50%	22.54%	22.59%	22.64%	22.69%	22.74%	22.78%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	17.09%	17.09%	17.09%	17.09%	17.09%	17.09%	17.09%	17.09%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

ALKEM Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

ALKEM Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

ALKEM Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹6,973.44

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹6,101.76

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 28x P/E.

🐻 Bear Case (15%) -12.0%

₹4,794.24

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 19:58 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Alkem Laboratories Ltd (ALKEM)	Target Stock	₹5,448.00	+0.92%	27.9x	18.9%	21.2%	0.15	₹62,625 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	19:58:58 IST	✓ Live Sync
Financial Statements (10Y)	Alkem Laboratories Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Alkem Laboratories Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Alkem Laboratories Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title